No connection

Search Results

ARCT

BEARISH
$6.68 Live
Arcturus Therapeutics Holdings Inc. · NASDAQ
Target $23.44 (+251.0%)
$5.85 52W Range $24.17

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Mar 14, 2026
Market cap
$189.87M
P/E
N/A
ROE
-28.9%
Profit margin
-80.2%
Debt/Equity
0.12
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.

Key Strengths

Analyst consensus is 'buy' with a target price of $23.44, implying significant upside potential
Insider sentiment is moderately positive at 40/100, suggesting some confidence in long-term prospects
Strong liquidity with a current ratio of 6.64 and quick ratio of 6.50, indicating robust short-term financial health
Debt/Equity ratio of 0.12 is low, indicating minimal leverage risk
Recent quarterly earnings surprises have been positive in several quarters, including a +74.6% surprise in Q4 2024

Key Risks

Piotroski F-Score of 0/9 indicates extreme financial instability and operational failure across all nine criteria
Revenue declined 68.4% YoY, signaling a severe contraction in business activity
Negative profit margins across all measures: -80.19% (net), -435.06% (operating), -36.79% (gross)
ROE of -28.92% and ROA of -15.50% reflect inefficient use of capital and deteriorating profitability
No free cash flow or operating cash flow data available, suggesting inability to generate sustainable cash from operations

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
15
Weak
Value
30
Future
20
Past
15
Health
10
Dividend
0
AI Verdict
bearish
Key drivers: Piotroski F-Score of 0/9, Negative revenue and earnings growth, Negative profitability across all metrics, Lack of cash flow generation, High volatility and long-term price decline
Confidence
85%
Value
30/100

Ref P/E, PEG, Graham Number

Positives
  • Price/Book of 0.89 suggests trading below book value
  • Low market cap ($0.19B) may attract speculative interest
Watchpoints
  • No Graham Number or intrinsic value available due to negative earnings and lack of stable growth
  • Price/Sales of 2.31 is elevated for a company with negative revenue growth
  • Forward P/E of -1.61 indicates no earnings-based valuation support
Future
20/100

Ref Growth rates

Positives
  • Analyst target price of $23.44 implies strong growth expectations
  • Recent quarters show positive earnings surprises, suggesting potential for recovery
Watchpoints
  • Revenue growth is -68.4% YoY, indicating ongoing business contraction
  • Earnings growth is not available, but historical trends show erratic and negative performance
  • No clear path to profitability or sustainable revenue generation
Past
15/100

Ref Historical trends

Positives
  • Some quarters show significant positive earnings surprises (e.g., +253.1% in 2023-Q1)
  • Historical EPS growth was positive in 2021-2022, though volatile
Watchpoints
  • Most recent Q/Q EPS growth is -110.2%, indicating worsening performance
  • 5-year price change of -87.2% reflects prolonged underperformance
  • Persistent losses and declining margins over multiple years
Health
10/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Low debt/equity ratio (0.12) and high current/quick ratios (6.64, 6.50) indicate strong liquidity
  • No Altman Z-Score available, but low leverage reduces immediate bankruptcy risk
Watchpoints
  • Piotroski F-Score of 0/9 is the lowest possible, indicating complete failure in financial health criteria
  • Negative ROE, ROA, and ROIC suggest capital is being destroyed
  • No operating or free cash flow data implies inability to fund operations sustainably
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend yield or payout ratio available
  • Dividend strength is 0/100, indicating no dividend policy
  • Negative earnings make dividend payments impossible

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$6.68
Analyst Target
$23.44
Upside/Downside
+251.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ARCT and closest competitors.

Updated 2026-03-13
ARC
Arcturus Therapeutics Holdings Inc.
Primary
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
SMT
Sanara MedTech Inc.
Peer
5Y
-25.6%
3Y
-56.6%
1Y
-29.4%
6M
-26.5%
1M
+11.3%
1W
+25.6%
RNA
Cartesian Therapeutics, Inc.
Peer
5Y
-93.8%
3Y
-80.8%
1Y
-33.0%
6M
-21.9%
1M
+5.9%
1W
+17.7%
ACB
Aurora Cannabis Inc.
Peer
5Y
-96.9%
3Y
-52.9%
1Y
-20.2%
6M
-29.6%
1M
-0.3%
1W
-2.3%
ADA
Adagene Inc.
Peer
5Y
-81.2%
3Y
+188.8%
1Y
+109.6%
6M
+84.4%
1M
+33.2%
1W
+45.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-1.61
PEG Ratio
N/A
P/B Ratio
0.89
P/S Ratio
2.31
EV/Revenue
-0.2
EV/EBITDA
0.22
Market Cap
$189.87M

Profitability

Profit margins and return metrics

Profit Margin -80.19%
Operating Margin -435.06%
Gross Margin -36.79%
ROE -28.92%
ROA -15.5%

Growth

Revenue and earnings growth rates

Revenue Growth -68.4%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.12
Low debt
Current Ratio
6.64
Strong
Quick Ratio
6.5
Excellent
Cash/Share
$8.12

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-11
$N/A
2026-03-03
$-1.03
-36.4% surprise
2025-11-10
$-0.49
+38.7% surprise
2025-08-11
$-0.34
+59.8% surprise

Healthcare Sector Comparison

Comparing ARCT against 560 companies in the Healthcare sector (34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-28.92%
This Stock
vs
-88.14%
Sector Avg
-67.2% (Below Avg)
Profit Margin
-80.19%
This Stock
vs
-16.28%
Sector Avg
+392.6% (Superior)
Debt to Equity
0.12
This Stock
vs
2.66
Sector Avg
-95.6% (Less Debt)
Revenue Growth
-68.4%
This Stock
vs
124.04%
Sector Avg
-155.1% (Slower)
Current Ratio
6.64
This Stock
vs
4.47
Sector Avg
+48.3% (Stronger)

Similar Companies

Peer comparison within the same industry

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
9 analysts
Citigroup
2026-03-05
Maintains
Buy Buy
Citigroup
2026-03-04
Maintains
Neutral Neutral
Piper Sandler
2026-03-04
Maintains
Overweight Overweight
Citigroup
2026-01-06
Maintains
Neutral Neutral
Citigroup
2025-11-13
Maintains
Neutral Neutral
Piper Sandler
2025-11-11
Maintains
Overweight Overweight
HC Wainwright & Co.
2025-11-11
Maintains
Neutral Neutral
HC Wainwright & Co.
2025-10-24
down
Buy Neutral
Citigroup
2025-10-23
down
Buy Neutral
Wells Fargo
2025-10-23
Maintains
Overweight Overweight

Past News Coverage

Recent headlines mentioning ARCT from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile